Cell Therapy Services Your Product. Our Passion.

Size: px
Start display at page:

Download "Cell Therapy Services Your Product. Our Passion."

Transcription

1 Pharma&Biotech Cell Therapy Services Your Product. Our Passion. Complete Portfolio of Services for cgmp Manufacturing of Cell-based Products

2 Pharma&Biotech Cell Therapy Services for cgmp Manufacturing of Cell-based Products Cell Therapy from Lonza Lonza s commitment is to provide the highest quality service to support the rapid clinical development and commercial manufacturing of cellular therapeutics. Our global leadership in custom manufacturing for the pharmaceutical industry offers the ability to develop robust commercial manufacturing processes for cell therapy with our world-class current Good Manufacturing Practices (cgmp). Lonza has experience working with cell therapy developers at all stages of clinical development. A team of technical professionals will work diligently to help you source tissues, improve processes and test procedures, as well as implement cost-effective manufacturing technologies for autologous and allogeneic therapies. Through all phases of clinical development, the Lonza Team can address all aspects of cell therapy manufacturing in order to increase the likelihood of commercial success. 2

3 Service Offerings Consulting Services Tissue Acquisition Development Services Analytical Development Media Development Allogeneic Development Services Autologous Development Services cgmp-compliant Manufacturing Allogeneic and Autologous Cell Therapy Manufacturing World Class Quality Systems Biopreservation/Fill & Finish Biopreservation Fill & Finish Storage and Distribution Cell Therapy Manufacturing Sites Consulting Services Lonza has extensive experience manufacturing cell, viral and proteinbased therapeutics. Leverage Lonza s experience for guidance on a variety of topics including: Regulatory Filing Facility Design cgmp Compliance Cost of Goods Optimization Assay Selection/Development Path to Commercialization Tissue Acquisition Let Lonza s Expert Team help you navigate the complexities of tissue sourcing logistics and regulatory hurdles. As an AATB (American Association of Tissue Banks) accredited, FDA-registered and statelicensed tissue bank, we provide the support you need. Our Team of experienced tissue banking professionals builds specific donor, tissue and cell programs to accommodate each client s unique plans. To assist clients in complying with current donor eligibility requirements, the Tissue Acquisition Team develops programs in accordance with 21 CFR Part 1271 (HCT/P) while ethically sourcing human tissues. Our clients may reference Lonza s Human Tissue and Cells Donor Programs Type V DMF in their regulatory submissions to the US FDA. We Maintain the Following FDA-registered facility for human cells, tissues, and cellular and tissue-based products Licensed by the states of Maryland, New York and California AATB accredited Our Staff Experience in designing donor programs to meet global regulatory requirements Comprised of a team of scientists, one of whom serves on the Standards Committee of the AATB, physicians with in-depth expertise in donor testing and eligibility criteria, and specialists who handle logistics, control, and documentation CITI-certified (Collaborative Institutional Training Initiative) in Protection of Human Research Subjects 3

4 Pharma&Biotech Cell Therapy Services for cgmp Manufacturing of Cell-based Products Development Services Lonza understands the unique needs of clients ranging from early stage clinical trials, all the way through to licensure. Each Lonza partner is assigned a team of scientists to work with you to transform your process into a closed-system, scalable process that is compliant with cgmps. Your modified cell culturing process will be optimized to help ensure that your product maintains its critical quality attributes that will be validated by customized analytical testing. Analytical Development We have the knowledge and experience to qualify and validate your existing assays necessary for product release testing. Your designated team of scientists can also develop customized tests of your product, where necessary, which may be used for product characterization, formal comparability studies, and/or release testing. Additionally, our expertise in cell-based assays and in-depth knowledge of flow cytometry can be leveraged for the development of potency assays. Media Development As a tools and service provider, Lonza is uniquely positioned to work with our partners to develop a custom medium that will maximize the yield and/or performance of your product cells. Optimization of Lonza Media early in clinical development minimizes the impact to product comparability. Lonza Custom Media are formulated to help ensure they are amenable to closed-system, scalable cell processing. Allogeneic Development Services Our scientists and engineers are innovators of tools and techniques that facilitate closed-system, large volume downstream processing that is gentle enough for cell-based products. The Lonza Team is poised to transition your process to a scalable, closed-system process while maintaining the comparable biological activities of your product and, at the same time, controlling the cost of goods for manufacturing your product. Lonza is globally recognized for our experience in allogeneic cell therapy manufacturing. Lonza scientists have extensive experience developing and executing large-scale, closed-system processing for universal donor cell-based products. Autologous Development Services Lonza is prepared to face the challenges presented by the manufacture of patient-specific products. Our process engineers can model each client process in order to best understand key cost drivers and processing bottlenecks. Once modeled, Lonza scientists work to develop a streamlined, closed-system process that maintains the critical quality attributes of your product. We have dedicated state-of-the-art autologous cell processing suites at all of our cell therapy manufacturing sites. Our autologous processing suites were designed with safeguards in place to help ensure lot segregation. 4

5 cgmp-compliant Manufacturing At each of our Cell Therapy manufacturing sites, Lonza offers multiple suites of varying sizes and flexible design. Our suite design can be adapted to meet your needs. All sites offer specialized processing equipment for isolation, large-scale cell culture, and volume reduction. Our rigorous training program helps ensures that our staff is experienced with the procedures required to execute your manufacturing protocol. Lonza has experience manufacturing allogeneic/universal donor products as well as autologous/patient-specific products, including gene-modified cellular immunotherapies. Cell Expansion Allogeneic/Universal Donor Master Cell Bank Lot Tested Working Cell Bank Lot Tested Patient Doses Lot Tested Lonza s world-class quality systems help ensure global regulatory compliance of our Cell Therapy manufacturing processes and products. We source the highest-grade materials for the products we manufacture. Unidirectional material movement and personnel flow are available for your manufacturing technology needs in nearly all of our Cell Therapy manufacturing suites at Lonza s sites. Our paperless environmental monitoring helps ensure the quality of the manufacturing setting while streamlining batch record documentation. Our dedication to operational excellence allows for the establishment of efficient process protocols, which minimizes wasted time and reduces the number of manufacturing deviations. Furthermore, we can address your product labeling and document needs, prepare and approve all regulated documents prior to submission, and will gladly consult with the regulatory agencies during audits. Cell Expansion or Purification Autologous/Patient-specific Testing Patient or Donor Master Cell Bank Ampoule or Dose Working Cell Bank Ampoule or Dose Submitted for Testing Universal donor and patient-specific products present unique manufacturing and testing challenges. Lonza has the experience and infrastructure to manufacture both types of products according to cgmps, globally. 5

6 Pharma&Biotech Cell Therapy Services for cgmp Manufacturing of Cell-based Products Biopreservation/Fill & Finish Biopreservation The Lonza Team has experience with the formulation and biopreservation of a wide range of product types. We have expertise optimizing the formulation of fresh (non-frozen), cell-based products in order to extend non-frozen shelf-life. Additionally, we can optimize cryopreservation formulation and freeze parameters to maximize viable cell recovery. Moreover, we optimize thawing protocols for clinical trials sites in order to minimize the risks of delayed onset cell death in your product. Fill & Finish Lonza offers the filling of closed vials for cell-based products that is scalable to thousands of vials/hour in a cgmp-compliant clean room setting. Additionally, we offer closed-system bag filling for both autologous products as well as low volume allogeneic products. Storage and Distribution Lonza is equipped to establish and maintain a cold chain for all of your cryostorage needs for both cell banks and product doses. All Cell Therapy manufacturing sites maintain a Dewar farm for the storage of cell-based products in vapor-phase liquid nitrogen. Our storage warehouse is equipped with redundant automated monitoring systems to help ensure the safety and security of all stored Master Cell Banks (MCBs)and products. Cell-based products can be distributed globally using dry shippers with temperature monitoring to help ensure even and consistent temperature for your product while in transit. 6

7 Cell Therapy Manufacturing Sites Lonza Walkersville, MD USA Nine operational manufacturing suites State-of-the-art dedicated autologous suite (EU Grade B) Full US compliance with ISO 7 (Class 10,000) classification Four EU Grade B suites, compliant with European regulatory standards On-site manufacture of powder and liquid media On-site quality control testing and quality assurance specialists Lonza Houston, Texas USA Two segregated manufacturing suites for autologous cell processing Designed to meet EU Grade B Standards 100% single pass air to support ex-vivo transduction utilizing viral vectors On-site manufacture of viral vectors On-site quality control testing and quality assurance specialists Lonza Verviers, Belgium Four segregated cgmp certified (EU Grade B suites) manufacturing suites Inspected and approved by the Belgium Authorities On-site manufacture of powder and liquid media On-site quality control testing and quality assurance specialists Lonza Tuas, Singapore Two state-of-the-art EU Grade B suites, with capacity to build out (commercial scale) Capacity to build a dedicated autologous suite (EU Grade B) On-site manufacture of liquid media On-site quality control testing and quality assurance specialists Houston, TX (USA) Cell and Viral-based Therapeutics Cell & Gene Immunotherapies Viral Vectors Autologous Cell Processing Walkersville, MD (USA) Cell Therapy Autologous & Allogeneic Cell Bioassays & Reagents Process R&D Services Media Custom Media & Buffers Bioprocess Containers Verviers (Belgium) Cell Therapy Autologous & Allogeneic Cell Bioassays & Reagents Process R&D Services Media Custom Media & Buffers Bioprocess Containers Tuas (Singapore) Cell Therapy Autologous & Allogeneic Cell Bioassays & Reagents Process R&D Services Media Custom Media & Buffers Bioprocess Containers 7

8 Contact Information North America Lonza Walkersville, Inc Biggs Ford Road Walkersville, MD Tel [toll free] Lonza Houston, Inc El Rio Street Houston, TX Tel [toll free] Europe Lonza Verviers Sprl Parc Industriel de Petit-Rechain 4800 Verviers, Belgium Tel celltherapy@lonza.com International Lonza BioSciences Singapore Pte Ltd 25 Tuas South Avenue 6 SG-Singapore Tel celltherapy@lonza.com Lonza Walkersville, Inc. Walkersville, MD Unless otherwise noted, all trademarks herein are marks of the Lonza Group or its affiliates. The information contained herein is believed to be correct and corresponds to the latest state of scientific and technical knowledge. However, no warranty is made, either expressed or implied, regarding its accuracy or the results to be obtained from the use of such information and no warranty is expressed or implied concerning the use of these products. The buyer assumes all risks of use and / or handling. Some products may not be available in all markets or for every type of application. Any user must make his own determination and satisfy himself that the products supplied by Lonza Group Ltd and the information and recommendations given by Lonza Group Ltd are (i) suitable for intended process or purpose, (ii) in compliance with environmental, health and safety regulations, and (iii) will not infringe any third party s intellectual property rights. No statement is intended or should be construed as a recommendation to infringe on any existing patent. Copyright 2012, Lonza Walkersville, Inc. All rights reserved. BR-CTCap-2 11/12 CT-BR002

Global Integrated Solutions. Advanced Therapy Clinical Development and Commercialization

Global Integrated Solutions. Advanced Therapy Clinical Development and Commercialization Global Integrated Solutions Advanced Therapy Clinical Development and Commercialization There There is is a patient patient waiting. waiting. Fisher BioServices ensures that your advanced therapy product

More information

Potelligent CHOK1SV. How It Works. Potelligent CHOK1SV

Potelligent CHOK1SV. How It Works. Potelligent CHOK1SV Potelligent CHOK1SV Potelligent CHOK1SV Potelligent CHOK1SV How It Works A new host cell line for the production of recombinant antibodies has been developed through close collaboration between Lonza and

More information

Manufacturing centre

Manufacturing centre Manufacturing centre To help support the growing industry, we have built a large-scale GMP manufacturing centre, which through collaborations, will help address the manufacturing challenges faced by therapy

More information

Table of Contents. Welcome to Dishman. Our Mission. Our Focus: Client Satisfaction

Table of Contents. Welcome to Dishman. Our Mission. Our Focus: Client Satisfaction Welcome to Dishman Our Mission Dishman Group continually invests in the global pharmaceutical industry, ensuring Dishman s business can provide pharmaceutical customers with high-value, high-quality products

More information

The Elite Provider. Cell & Gene. Therapy Manufacturing

The Elite Provider. Cell & Gene. Therapy Manufacturing The Elite Provider Cell & Gene Therapy Manufacturing GMP Manufacturing Services The cgmp manufacturing in Vigene is compliant with US FDA and EU EMA regulatory requirements. The manufacturing area consists

More information

Lonza Nansha, China For Global Excellence in Advanced Chemical Synthesis

Lonza Nansha, China For Global Excellence in Advanced Chemical Synthesis Pharma&Biotech Lonza Nansha, China For Global Excellence in Advanced Chemical Synthesis Lonza Guangzhou Nansha Ltd «Twenty-five years ago Lonza built one of the world s most advanced cgmp chemical manufacturing

More information

3M Drug Delivery Systems. April 26, 2011

3M Drug Delivery Systems. April 26, 2011 3M MDI Manufacturing April 26, 2011 3M Drug Delivery Systems Drug Delivery Systems Overview 3M Drug Delivery Systems is a division of 3M that is dedicated to the development and manufacturing of inhalation

More information

Global Sterile Liquid Capabilities

Global Sterile Liquid Capabilities Global Sterile Liquid Capabilities The life science business of Merck operates as MilliporeSigma in the U.S. and Canada. WHY US? Our Global Sterile Liquid capabilities are designed to enhance and streamline

More information

Precision Biospecimen Solutions: Paving the Way to Personalized Medicine

Precision Biospecimen Solutions: Paving the Way to Personalized Medicine Precision Biospecimen Solutions: Paving the Way to Personalized Medicine ACCELERATING RESEARCH. IMPROVING OUTCOMES. The companies under the Precision for Medicine banner deliver specialized strategic and

More information

Investor Presentation

Investor Presentation Investor Presentation December 2013 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform

More information

MDI Manufacturing Services

MDI Manufacturing Services MDI Manufacturing Services Presenter, Date Who we are 3M Drug Delivery Systems is a division of 3M dedicated to working together with pharmaceutical and biotech companies to bring new and improved products

More information

BioWhittaker Specialty Media Maximize Your Cell Growth and Productivity

BioWhittaker Specialty Media Maximize Your Cell Growth and Productivity BioResearch BioWhittaker Specialty Media Maximize Your Cell Growth and Productivity BioWhittaker Specialty Media cell culture applications BioResearch BioWhittaker Specialty Media Maximize Your Cell Growth

More information

THERAPEUTIC AREAS CARDIOVASCULAR RESEARCH

THERAPEUTIC AREAS CARDIOVASCULAR RESEARCH THERAPEUTIC AREAS CARDIOVASCULAR RESEARCH PPD S CARDIOVASCULAR TEAM: OPTIMIZING TRIALS AND IMPROVING OUTCOMES APPLYING EXPERIENCE, INNOVATION AND EFFICIENCY IN THE FIGHT AGAINST CARDIOVASCULAR DISEASE

More information

BioWhittaker Specialty Media Maximize Your Cell Growth and Productivity

BioWhittaker Specialty Media Maximize Your Cell Growth and Productivity BioResearch BioWhittaker Specialty Media Maximize Your Cell Growth and Productivity BioWhittaker Specialty Media Cell Culture Applications BioResearch BioWhittaker Specialty Media Maximize Your Cell Growth

More information

Adoptive cellular therapies are based on the administration of live cells into a patient in order for them to serve a therapeutic purpose.

Adoptive cellular therapies are based on the administration of live cells into a patient in order for them to serve a therapeutic purpose. Adoptive cellular therapies are based on the administration of live cells into a patient in order for them to serve a therapeutic purpose. Pharmaceutical products have been historically made of purified

More information

ABOUT GLYCOSTEM. Company Overview

ABOUT GLYCOSTEM. Company Overview ABOUT GLYCOSTEM The company is a clinical stage biotech company established in the Netherlands in 2007. The company s headquarters and new state-of-the-art lab and production facilities are based at Pivot

More information

Inspections, Compliance, Enforcement, and Criminal Investigations

Inspections, Compliance, Enforcement, and Criminal Investigations Home Inspections, Compliance, Enforcement, and Criminal Investigations Enforcement Actions Warning Letters Inspections, Compliance, Enforcement, and Criminal Investigations Celltex Therapeutics Corporation

More information

COGS by Design: a systems approach to achieving commercially viable cellular therapy products. Tim Oldham 27 May 2016 ISCT 16 - Singapore

COGS by Design: a systems approach to achieving commercially viable cellular therapy products. Tim Oldham 27 May 2016 ISCT 16 - Singapore COGS by Design: a systems approach to achieving commercially viable cellular therapy products Tim Oldham 27 May 2016 ISCT 16 - Singapore Summary Identifying the total needle-to-needle cost of therapy to

More information

Sharon Tindle, MS, CQA (ASQ) QA Manager, BMT Tissue Services Mount Sinai Hospital, New York, NY. June 7, 2016

Sharon Tindle, MS, CQA (ASQ) QA Manager, BMT Tissue Services Mount Sinai Hospital, New York, NY. June 7, 2016 Sharon Tindle, MS, CQA (ASQ) QA Manager, BMT Tissue Services Mount Sinai Hospital, New York, NY June 7, 2016 1 Brief description of the Mount Sinai Cellular Therapy Laboratory Overview of BM transplant

More information

WinKQCL 5 Endotoxin Detection and Analysis Software We Analyze Endotoxin Data Every Day

WinKQCL 5 Endotoxin Detection and Analysis Software We Analyze Endotoxin Data Every Day Pharma&Biotech WinKQCL 5 Endotoxin Detection and Analysis Software We Analyze Endotoxin Data Every Day For Endotoxin Detection Pharma&Biotech WinKQCL 5 Software for Endotoxin Detection and Analysis WinKQCL

More information

Cell and gene therapy: scaling up and moving to mass production

Cell and gene therapy: scaling up and moving to mass production EDITORIAL Cell and gene therapy: scaling up and moving to mass production Nigel Whittle In order to fulfil the promise of cell therapy, it is important that manufacture of these therapies can be industrialized

More information

Applied Protein Services

Applied Protein Services Applied Protein Services Applied Protein Services A Window into the Future Development risk and attrition rates remain two of the greatest challenges to a successful biopharmaceutical pipeline. To help

More information

Contact details: Anna Silvani

Contact details: Anna Silvani Consultation Document Good Manufacturing Practice for Advanced Therapy Medicinal Products MolMed comments to the DG SANTE consultation on GMPs for ATMPs pursuant to Article 5 of Regulation 1394/2007. MolMed

More information

Services for Medical Devices. Expert solutions for product development from concept to commercialization

Services for Medical Devices. Expert solutions for product development from concept to commercialization Services for Medical Devices Expert solutions for product development from concept to commercialization Services for Medical Devices WuXi AppTec s comprehensive testing programs and expert guidance help

More information

Product Testing & Release. PACT Workshop: Design & Operation of GMP Cell Therapy Facilities April 4 th /5 th, 2006

Product Testing & Release. PACT Workshop: Design & Operation of GMP Cell Therapy Facilities April 4 th /5 th, 2006 Product Testing & Release PACT Workshop: Design & Operation of GMP Cell Therapy Facilities April 4 th /5 th, 2006 Product Testing Used to determine Safety, Purity, Identity, Potency, etc. Suitability of

More information

Partner with the Global Leader in Drug Delivery Systems

Partner with the Global Leader in Drug Delivery Systems 3M DRUG DELIVERY SYSTEMS Partner with the Global Leader in Drug Delivery Systems Northridge, CA, USA Manufacturing Facility Experts at Commercializing Innovation 3M: Transforming New Ideas into Thousands

More information

CMC Considerations for Manufacturing of CAR T-Cell Product

CMC Considerations for Manufacturing of CAR T-Cell Product CMC Considerations for Manufacturing of CAR T-Cell Product November 14, 2017 Joann M. Parker, R.Ph, M.S. Regulatory Global CMC; Pfizer Inc Session: New Modalities for Cancer Moonshot: Unique Regulatory,

More information

Raw materials for cell & gene therapy: exploring regulatory and supply issues

Raw materials for cell & gene therapy: exploring regulatory and supply issues CELL & GENE THERAPY RAW MATERIALS: GETTING IT RIGHT FROM THE START INNOVATOR INSIGHT Raw materials for cell & gene therapy: exploring regulatory and supply issues As Vice President of Development & Production

More information

Cell Therapy Product Manufacturing Considerations. July 17, 2017 CMC Strategy Forum Mo Heidaran, Ph.D.

Cell Therapy Product Manufacturing Considerations. July 17, 2017 CMC Strategy Forum Mo Heidaran, Ph.D. Cell Therapy Product Manufacturing Considerations July 17, 2017 CMC Strategy Forum Mo Heidaran, Ph.D. Office of Tissues and Advanced Therapies FDA/CBER Overview Establishing Manufacturing Control Applying

More information

Eva Martinez Caceres Anja ten Brinke Piotr Trzonkowski

Eva Martinez Caceres Anja ten Brinke Piotr Trzonkowski Barcelona 11.11.2015 Comments on Good Manufacturing Practice for Advanced Therapy Medicinal Products Dear Sirs, With this letter we are sending our comments on Good Manufacturing Practice for Advanced

More information

GMP. Safeguard The Patient s Health.

GMP. Safeguard The Patient s Health. GMP Safeguard The Patient s Health. Scope. Products and testing according to pharma industry standard. Good Manufacturing Practice or GMP are practices and systems that are required to be adapted in pharmaceutical

More information

Eden Biodesign ebook. Celebrating 10 Years of Success

Eden Biodesign ebook. Celebrating 10 Years of Success Eden Biodesign ebook Celebrating 10 Years of Success Eden Biodesign ebook Chapter 1: Overview Chapter 2: Our History Chapter 3: Much More than a CMO Chapter 4: Key Milestones Chapter 5: About Eden Biodesign

More information

Whitepaper. Small Molecule Vs Cell Therapy Clinical Trial Supply Chain. Martin Lamb, Executive Vice President for Sales and Marketing

Whitepaper. Small Molecule Vs Cell Therapy Clinical Trial Supply Chain.  Martin Lamb, Executive Vice President for Sales and Marketing Small Molecule Vs Cell Therapy Clinical Trial Supply Chain Page 1 Whitepaper Small Molecule Vs Cell Therapy Clinical Trial Supply Chain Martin Lamb, Executive Vice President for Sales and Marketing Small

More information

Cell Characterization: Developing Assays to Address the Biological Parameters of Identity and Potency

Cell Characterization: Developing Assays to Address the Biological Parameters of Identity and Potency Cell Characterization: Developing Assays to Address the Biological Parameters of Identity and Potency Jessica Carmen Ph.D and Jon Rowley Ph.D., LBS-TCS, May 2011 Disclaimer Certain matters discussed in

More information

Challenges associated with supply to larger patients populations: Elements of the CTL019 experience

Challenges associated with supply to larger patients populations: Elements of the CTL019 experience Cell and Gene Therapy Challenges associated with supply to larger patients populations: Elements of the CTL019 experience Daniel Stark Head External Supply Cell- and Gene Therapies Development and Manufacturing

More information

COMPANY PROFILE. Dishman offers innovation, security of supply and value for money. Dishman Group. Research EARLY STAGE API. Preclinical.

COMPANY PROFILE. Dishman offers innovation, security of supply and value for money. Dishman Group. Research EARLY STAGE API. Preclinical. COMPANY PROFILE Dishman is a global outsourcing partner for the pharmaceutical industry offering a portfolio of development, scale-up and services. Dishman improves its customers businesses by providing

More information

PRIME-XV T CELL CDM. Chemically-defined, animal component-free medium for T cell culture

PRIME-XV T CELL CDM. Chemically-defined, animal component-free medium for T cell culture T CELL CDM Chemically-defined, animal component-free medium for T cell culture Chemically-defined, animal component-free formula delivers optimal performance Optimized to support vigorous growth while

More information

Product lifecycle management in one site

Product lifecycle management in one site Product lifecycle management in one site Today s world provides multiple opportunities for a biopharma company. An aging global population and the prevalence of chronic and communicable diseases are creating

More information

Pharma&Biotech. Developability Assessment Platform Reduce Attrition Rates, Improve Clinical Safety and Avoid the Valley of Death

Pharma&Biotech. Developability Assessment Platform Reduce Attrition Rates, Improve Clinical Safety and Avoid the Valley of Death Pharma&Biotech Developability Assessment Platform Reduce Attrition Rates, Improve Clinical Safety and Avoid the Valley of Death The Valley of Death Development risk, safety and high attrition rates remain

More information

Staffing - Medical Devices

Staffing - Medical Devices Staffing - Medical Devices LONDON GENEVA SINGAPORE DUBLIN procorre.com 1 Implementing solutions to clients worldwide 2 Contents Services 04 Sector Overview 07 Medical Devices 07 In-Vitro Diagnostics 08

More information

FDA Approach to the Regulation of Hematopoietic Stem/Progenitor Cells (HPC)

FDA Approach to the Regulation of Hematopoietic Stem/Progenitor Cells (HPC) FDA Approach to the Regulation of Hematopoietic Stem/Progenitor Cells (HPC) Ellen Lazarus, M.D. Medical Officer Division of Human Tissues Office of Cellular, Tissue, and Gene Therapies FDA proposed approach

More information

COUNT ON US FROM NON-STERILE TO STERILE FROM GELS AND CREAMS TO OINTMENTS AND AEROSOLS FROM CONCEPT TO COMMERCIALIZATION FROM VIRTUAL TO LARGE PHARMA

COUNT ON US FROM NON-STERILE TO STERILE FROM GELS AND CREAMS TO OINTMENTS AND AEROSOLS FROM CONCEPT TO COMMERCIALIZATION FROM VIRTUAL TO LARGE PHARMA COUNT ON US FROM NON-STERILE TO STERILE FROM GELS AND CREAMS TO OINTMENTS AND AEROSOLS FROM CONCEPT TO COMMERCIALIZATION FROM VIRTUAL TO LARGE PHARMA WHO WE ARE DPT is a Contract Development and Manufacturing

More information

QP Essentials: Your EU Gateway to Clinical and Commercial Distribution of Cell-Based Therapeutics

QP Essentials: Your EU Gateway to Clinical and Commercial Distribution of Cell-Based Therapeutics QP Essentials: Your EU Gateway to Clinical and Commercial Distribution of Cell-Based Therapeutics By Colin Grant, Quality and Regulatory Manager, Fisher BioServices 1 Share th is eb o o k! www.fis herbios

More information

Your Complete Quality Solution Provider for the Life Science Industry

Your Complete Quality Solution Provider for the Life Science Industry Your Complete Quality Solution Provider for the Life Science Industry PQE at-a-glance Our broad services portfolio, extensive experience, effective project management, and exceptional cost effectiveness,

More information

Regulatory Approval of Modern Gene-Based Cancer Immunotherapies CAR T Cells A product perspective

Regulatory Approval of Modern Gene-Based Cancer Immunotherapies CAR T Cells A product perspective Regulatory Approval of Modern Gene-Based Cancer Immunotherapies CAR T Cells A product perspective ASQ509 Biomed/Biotech SIG 2/1/18 Xiaobin Victor Lu Division of Cellular and Gene Therapies Office of Tissues

More information

Product Testing & Release. PACT Workshop: Design & Operation of GMP Cell Therapy Facilities April 10 th /11 th, 2007

Product Testing & Release. PACT Workshop: Design & Operation of GMP Cell Therapy Facilities April 10 th /11 th, 2007 Product Testing & Release PACT Workshop: Design & Operation of GMP Cell Therapy Facilities April 10 th /11 th, 2007 Product Testing Used to determine Safety, Purity, Identity, Potency, Quality Suitability

More information

Mapping Success for Commercial Cell Therapy Manufacturing 100% 50% 0% 100% 50% 0% 100% 50% Realization

Mapping Success for Commercial Cell Therapy Manufacturing 100% 50% 0% 100% 50% 0% 100% 50% Realization BioProcess TM I N T E R N A T I O N A L C e l l T h e r a p y FACILITIES AND LOGISTICS Mapping Success for Commercial Cell Therapy Bob Preti, Ann M. Daus, Brian Hampson, and Cenk Sumen Commercializing

More information

Case Study: Examples Relating to the Quality Control of Cell-based Products

Case Study: Examples Relating to the Quality Control of Cell-based Products Case Study: Examples Relating to the Quality Control of Cell-based Products CMC Strategy Forum Japan 2014 Yuuki Miyatake1), 2) 1) TEIJIN PHARMA LIMITED 2) Japan Pharmaceutical Manufacturers Association

More information

Facility construction and start up for commercial scale manufacturing of monoclonal antibodies - a case study

Facility construction and start up for commercial scale manufacturing of monoclonal antibodies - a case study 24 th Interphex, Japan, Technical conference June 29 th, 2011 Michael Brown Facility construction and start up for commercial scale manufacturing of monoclonal antibodies - a case study Lonza overview

More information

Small Scale Bio-Manufacturing for Clinical Trails; an Introduction to the Clinical Biotechnology Centre

Small Scale Bio-Manufacturing for Clinical Trails; an Introduction to the Clinical Biotechnology Centre Small Scale Bio-Manufacturing for Clinical Trails; an Introduction to the Clinical Biotechnology Centre Keith Williams Business Development Manager - Clinical Biotechnology Centre CBC - Aims and Objectives

More information

Regulatory Issues in Human Subjects Research

Regulatory Issues in Human Subjects Research Regulatory Issues in Human Subjects Research Ian McNiece, PhD University of Miami Human Subjects Research Require IRB approval Studies of new drugs or applications of drugs require an FDA approved IND

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Cooperative Manufacturing Arrangements for Licensed Biologics Additional copies of this guidance are available from the Office of Communication, Training and Manufacturers Assistance

More information

Current Considerations on Chemistry, Manufacturing and Control of Cell Therapy Products (CTPs)

Current Considerations on Chemistry, Manufacturing and Control of Cell Therapy Products (CTPs) Current Considerations on Chemistry, Manufacturing and Control of Cell Therapy Products (CTPs) Wei Wei Ph.D Center for Drug Evaluation, National Medical Products Administration (CDE,NMPA) 2018/12/04 Tokyo

More information

Ancillary Materials for Cell & Tissue Therapies Definitions, US Regulatory Approach, and USP s Risk-Tiered Approach

Ancillary Materials for Cell & Tissue Therapies Definitions, US Regulatory Approach, and USP s Risk-Tiered Approach USP/ISCT Workshop 2012 Seattle, WA, USA Ancillary Materials for Cell & Tissue Therapies Definitions, US Regulatory Approach, and USP s Risk-Tiered Approach Elizabeth Read, MD Head of Product Development

More information

Osteobiologic B O N E G R A F T I N G S O L U T I O N S

Osteobiologic B O N E G R A F T I N G S O L U T I O N S Osteobiologic BONE GRAFTING SOLUTIONS The AlloSource Advantage Delivering Quality and Safety * Allografts labeled Sterile R are aseptically processed and packaged and then subjected to gamma irradiation.

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Cooperative Manufacturing Arrangements for Licensed Biologics DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding

More information

Pharma&Biotech. Translated versions available at

Pharma&Biotech. Translated versions available at Pharma&Biotech β-g-blocker Translated versions available at www.lonza.com Content Section Page No. Intended Use Warning Explanation of Test 2 Principle 3 Reagents Supplied and Storage Conditions 3 Procedure

More information

Cold-Chain & Logistical Challenges of Cell Therapeutics in Clinical Trials

Cold-Chain & Logistical Challenges of Cell Therapeutics in Clinical Trials Cold-Chain & Logistical Challenges of Cell Therapeutics in Clinical Trials Dan O Donnell Associate Director, Cell Therapy Logistics Fisher BioServices Part of Thermo Fisher Scientific Logistics of Biologics

More information

Quality development considerations - Regulatory perspective

Quality development considerations - Regulatory perspective Quality development considerations - Regulatory perspective CAT workshop on cell-based immunotherapies, London 15. 11.2016 Christiane Niederlaender CAT Member, MHRA An agency of the European Union Genetically

More information

Ensuring Quality & Regulatory Compliance when Collaborating with a Service Provider

Ensuring Quality & Regulatory Compliance when Collaborating with a Service Provider DPT Thought Leadership Issue 2 Ensuring Quality & Regulatory Compliance when Collaborating with a Service Provider I N T R O D U C T I O N In recent years, the pharmaceutical industry has given greater

More information

Phase Appropriate GMPs for IMPs. Presented by: Karen S. Ginsbury For: IFF, October 31, Nov 02, 2017

Phase Appropriate GMPs for IMPs. Presented by: Karen S. Ginsbury For: IFF, October 31, Nov 02, 2017 Phase Appropriate GMPs for IMPs Presented by: Karen S. Ginsbury For: IFF, October 31, Nov 02, 2017 1 Lets start with References https://mhrainspectorate.blog.gov.uk/2016/0 5/20/manufacture-of-investigationalmedicinal-products-frequently-askedquestions/

More information

CSL s Large Scale Cell Culture Facility

CSL s Large Scale Cell Culture Facility BioProcess Network 20 th October 2011 CSL s Large Scale Cell Culture Facility Tim Hughes Sr. Dir. Clinical Manufacturing CSL Objective How to maximise the opportunity to build a state-of-theart facility

More information

Manufacturing Integrated Biologics Manufacturing

Manufacturing Integrated Biologics Manufacturing Manufacturing Integrated Biologics Manufacturing Integrated Biologics Manufacturing Abzena provides customer focused process development and manufacturing services for cgmp and non-gmp production of recombinant

More information

Real solutions for real-world problems.

Real solutions for real-world problems. Digital Health Real solutions for real-world problems. Today, it costs around $2.6 billion and takes between 10 and 15 years to develop a new drug. 1 Despite the enormity of this investment, once the drug

More information

CQAs for C&GT Products to Enable Comparability Assessment. Ben Thompson Snr Director, Biopharmaceutical CMC RA GlaxoSmithKline

CQAs for C&GT Products to Enable Comparability Assessment. Ben Thompson Snr Director, Biopharmaceutical CMC RA GlaxoSmithKline CQAs for C&GT Products to Enable Comparability Assessment Ben Thompson Snr Director, Biopharmaceutical CMC RA GlaxoSmithKline Overview Demonstrate the value of defining CQAs early in product development

More information

Where Quality Meets Flexibility

Where Quality Meets Flexibility Where Quality Meets Flexibility is an industry leading 503B Outsourcing Facility providing sterile and non-sterile compounding services to hospitals, surgery centers, clinics, researchers & patients nationwide.

More information

PRAXIS. A publication by Bioengineering AG

PRAXIS. A publication by Bioengineering AG PRAXIS A publication by Bioengineering AG Portrait of Rentschler Biotechnologie GmbH, a globally active service company that supports its clients in the development, production, and registration of biopharmaceuticals.

More information

BioWhittaker specialty media Maximize your cell growth and productivity

BioWhittaker specialty media Maximize your cell growth and productivity BioResearch BioWhittaker specialty media Maximize your cell growth and productivity BioWhittaker specialty media cell culture applications BioResearch BioWhittaker specialty media Maximize your cell growth

More information

CONTRACT RESEARCH SERVICES

CONTRACT RESEARCH SERVICES 1537 NW 65th Avenue Plantation, FL 33313 USA Phone: (954) 321-8988 Fax: (954) 321-9778 info@receptopharm.com www.receptopharm.com ReceptoPharm has installed the pathways to develop, produce and supply

More information

Regulatory Challenges for the Licensure of Future Vaccines

Regulatory Challenges for the Licensure of Future Vaccines Regulatory Challenges for the Licensure of Future Vaccines Tong Wu, Ph.D. Bacterial & Combination Vaccine Division, BGTD, Health Canada June 26-29, 2018, Seoul, Korea, the Global Bio Conference 1 Disclaimer

More information

AdaptDose, an innovative platform that reduces product development time and costs by 30% or more

AdaptDose, an innovative platform that reduces product development time and costs by 30% or more WHITE PAPER January 2017 AdaptDose, an innovative platform that reduces product development time and costs by 30% or more Frontida BioPharm, Inc. Ron Connolly 01.01.2017 CONTENTS ABSTRACT INTRODUCTION

More information

Supplies and Reagents

Supplies and Reagents Supplies and Reagents PACT Workshop: Design & Operation of GMP Cell Therapy Facilities April 10 th -11 th, 2007 NHLBI-sponsored PACT Group Guidance for Industry INDs Approaches to Complying with CGMP During

More information

FROM CLINICAL TO COMMERCIAL CUSTOM CAN. An overview of our Development and Manufacturing capabilities

FROM CLINICAL TO COMMERCIAL CUSTOM CAN. An overview of our Development and Manufacturing capabilities FROM CLINICAL TO COMMERCIAL CUSTOM CAN An overview of our Development and Manufacturing capabilities THE CUSTOM DIFFERENCE Established in 1979, Custom Pharma Services has grown to become the go-to resource

More information

NUVISAN GROUP. Our Philosophy

NUVISAN GROUP. Our Philosophy NUVISAN GROUP Our Philosophy 2 EARLY DEVELOPMENT Introduction to Nuvisan Fully integrated Contract Research Organisation headquarted in Neu-Ulm, southern part of Germany. Nuvisan - Early Development Headquartered

More information

KryoSure and KryoVue Cryopreservation Products

KryoSure and KryoVue Cryopreservation Products KryoSure and KryoVue Cryopreservation Products Non-reactive fluorinated ethylene propylene (FEP) bags providing safe use, storage and transport for immunologic and biologic applications 301-990-1407 /

More information

Cell Therapy and Right First Time Manufacturing

Cell Therapy and Right First Time Manufacturing Cell Therapy and Right First Time Manufacturing How a Syncade MES solution reduces process risk Right Every First Time Manufacturing In cell therapy manufacturing, each batch must be perfect the first

More information

The importance of fill & finish in the commercialization of your cell & gene therapy

The importance of fill & finish in the commercialization of your cell & gene therapy OVERCOMING DOWNSTREAM BIOPROCESSING BOTTLENECKS INNOVATOR INSIGHT The importance of fill & finish in the commercialization of your cell & gene therapy Jean-Sébastien is Head of Sales at Aseptic Technologies,

More information

US FDA: CMC Issues for INDs

US FDA: CMC Issues for INDs ISBTC Global Regulatory Summit October 29, 2008 US FDA: CMC Issues for INDs Keith Wonnacott, Ph.D. keith.wonnacott@fda.hhs.gov US Food and Drug Administration Center for Biologics Evaluation and Research

More information

Supplies and Reagents

Supplies and Reagents Supplies and Reagents PACT Workshop: Design & Operation of GMP Cell Therapy Facilities April 4 th /5 th, 2006 NHLBI-sponsored PACT Group Guidance for Industry INDs Approaches to Complying with CGMP During

More information

Getting to the Factory of the Future

Getting to the Factory of the Future Patient-Specific Cell Therapy Getting to the Factory of the Future Robert A. Preti, PhD Chief Executive Officer and President, PCT General Manager, Global Regenerative Medicine Business Sector, Hitachi

More information

Medical Devices. Epicor for. Functionality. Meeting the Challenges for Medical Devices

Medical Devices. Epicor for. Functionality. Meeting the Challenges for Medical Devices Epicor for Medical Devices Functionality XXGlobal operations XXTraceability and quality XXCost management XXRapid configuration XXProduct lifecycle management XXRegulatory compliance XXFDA, cgmp, ISO,

More information

OUR MISSION OUR EXPERTISE OUR SERVICES

OUR MISSION OUR EXPERTISE OUR SERVICES Capacités Biotherapeutics Solutions (C.B.S) is a newly created business unit of CAPACITÉS LLC, an affiliate company of the University of Nantes (France). By gathering experts and core facilities, C.B.S

More information

NIA Aging Cell Repository Assurance Form for Cell Lines and DNA Samples

NIA Aging Cell Repository Assurance Form for Cell Lines and DNA Samples NIA Aging Cell Repository Assurance Form for Cell Lines and DNA Samples January 17, 2011 This Assurance Form pertains to access to cell lines and DNA samples that are part of the NIA Aging Cell Repository

More information

KINGSMANN CARE GROUP

KINGSMANN CARE GROUP PHARMA CONSULTANTS KINGSMANN CARE GROUP KINGSMANN CONSULTANCY SERVICES Thank you for taking interest in Kingsmann Consultancy Services. Kingsmann Consultancy (KC) is a leading business development-consulting

More information

Biotechpharma company profile. Romanas Ramanauskas Business development manager

Biotechpharma company profile. Romanas Ramanauskas Business development manager Biotechpharma company profile Romanas Ramanauskas Business manager October, 2012 1 Contents History Company overview Services and capabilities Expression system and process Technology scale-up and GMP

More information

A Life Cycle Approach to Raw Material Qualification for Cell and Gene Therapy Products

A Life Cycle Approach to Raw Material Qualification for Cell and Gene Therapy Products A Life Cycle Approach to Raw Material Qualification for Cell and Gene Therapy Products Angela Whatley, Ph.D. Office of Tissues and Advanced Therapies CBER/FDA CMC Strategy Forum on Cell & Gene Therapies

More information

IMLYGIC CASE STUDY: MANUFACTURING AND COMMERCIALIZATION OF AN ONCOLYTIC VIRUS PRODUCT

IMLYGIC CASE STUDY: MANUFACTURING AND COMMERCIALIZATION OF AN ONCOLYTIC VIRUS PRODUCT IMLYGIC CASE STUDY: MANUFACTURING AND COMMERCIALIZATION OF AN ONCOLYTIC VIRUS PRODUCT TIA BUSH VICE PRESIDENT, SITE OPERATIONS SERVING PATIENTS IS A PRIVILEGE 2 THIS PRIVILEGE COMES WITH SIGNIFICANT RESPONSIBILITIES

More information

Leader in Pharmaceutical Oral Films

Leader in Pharmaceutical Oral Films TSX-V: IGX OTCQX: IGXT Leader in Pharmaceutical Oral Films WE MAKE APPROVED DRUGS BETTER Our Mission We make approved drugs better, with next generation pharmaceutical products that address unmet medical

More information

Quality Manual. Quality Manual. Vera Bioscience / Anu Life Sciences. April 2018

Quality Manual. Quality Manual. Vera Bioscience / Anu Life Sciences. April 2018 Quality Manual Vera Bioscience / Anu Life Sciences April 2018 Page 1 of 15 TABLE OF CONTENTS Quality Manual Page 1. Company Overview 3 2. References 3 3. Exemptions, Alternatives and Variances 3 4. General

More information

ADB Consulting & CRO Inc.

ADB Consulting & CRO Inc. DATA MANAGEMENT, BIO-STATISTICS, CLINICAL OPERATIONS, QUALITY SYSTEMS & STAFFING SERVICES Abbreviated Edition December 2005 Advancing Data Management, Bio-statistics, Clinical Operations, & Quality Systems

More information

Comparability Studies for Autologous Cell Therapy Products. Chris Shen July, 2017

Comparability Studies for Autologous Cell Therapy Products. Chris Shen July, 2017 Comparability Studies for Autologous Cell Therapy Products Chris Shen July, 2017 Forward Looking Statements/Safe Harbor To the extent statements contained in this presentation are not descriptions of historical

More information

DEMONSTRATING YOUR MEDICINE S VALUE TO ALL STAKEHOLDERS TRUSTED COMMERCIALIZATION AND MARKET ACCESS EXPERTISE

DEMONSTRATING YOUR MEDICINE S VALUE TO ALL STAKEHOLDERS TRUSTED COMMERCIALIZATION AND MARKET ACCESS EXPERTISE CATALYSTS DRIVING SUCCESSFUL DECISIONS IN LIFE SCIENCES DEMONSTRATING YOUR MEDICINE S VALUE TO ALL STAKEHOLDERS TRUSTED COMMERCIALIZATION AND MARKET ACCESS EXPERTISE WHEN COMMERCIALIZING A MEDICINE, IT

More information

Thermo Scientific Nucleic Acid Technologies

Thermo Scientific Nucleic Acid Technologies Thermo Scientific Nucleic Acid Technologies Phosphoramidites for Oligonucleotide Synthesis High Purity Nucleotides and Polynucleotides Fluorescent Labeling and Detection Custom Chemistries Molecular Biology

More information

Outsource or in-house? The evolving role of analytical services in pharmaceutical manufacturing

Outsource or in-house? The evolving role of analytical services in pharmaceutical manufacturing Outsource or in-house? The evolving role of analytical services in pharmaceutical manufacturing By Impact Analytical Introduction About Impact Analytical Impact Analytical is a contract analytical testing

More information

Clinical Trial Supplies. Establishing Firm Grounds for your Trials

Clinical Trial Supplies. Establishing Firm Grounds for your Trials Clinical Trial Supplies Establishing Firm Grounds for your Trials Clinical Trial Logistics & Supplies The success of a clinical trial largely depends on its conduct, data management, statistical analysis

More information

Weigh Dispense Optimization. Rockwell Automation's open, modular weigh and dispense solution.

Weigh Dispense Optimization. Rockwell Automation's open, modular weigh and dispense solution. Weigh Dispense Optimization Rockwell Automation's open, modular weigh and dispense solution. Overview Improving business performance through increased focus on manufacturing operations is getting more

More information

Dedicated to Molecular Diagnostics

Dedicated to Molecular Diagnostics Dedicated to Molecular Diagnostics For Europe Sample & Assay Technologies QIAGEN s growing role in molecular diagnostics At QIAGEN, one of our key goals is to support clinical decision-making and improve

More information

PyroTec PRO Robotic Solution for Endotoxin Detection FAQs Tech Tips

PyroTec PRO Robotic Solution for Endotoxin Detection FAQs Tech Tips Bioscience Solutions PyroTec PRO Robotic Solution for Endotoxin Detection FAQs Tech Tips Move from Manual Benchtop Processes to an Automated Workflow PyroTec PRO Robotic Solution is a new automated, plate-based

More information

Regulatory Implications for Global Manufacturing Development of Regenerative Medicines

Regulatory Implications for Global Manufacturing Development of Regenerative Medicines Regulatory Implications for Global Manufacturing Development of Regenerative Medicines Katherine Tsokas, JD June 2017 Global Regulatory Affairs Janssen Research & Development, LLC Jessica Riley, Shells

More information

Copyright. Jeremiah J. Kelly (2015). All rights reserved. Further dissemination without express written consent strictly prohibited.

Copyright. Jeremiah J. Kelly (2015). All rights reserved. Further dissemination without express written consent strictly prohibited. Statutory Framework for Biologics Drugs Investigational Use Application IND Pre-Market Approval Applications 505(b)(1) NDA 505(b)(2) NDA 505(j) ANDA Over-the-Counter (OTC) Non- Rx Drugs Monograph Biologics

More information